Neuronetics Stock Plunges As Q2 Earnings Miss Expectations; Underwhelming Q3 Revenue Outlook

  • Neuronetics Inc STIM reported Q2 EPS loss of $(0.29) lower than $(0.41) posted a year ago, but missing the consensus of $(0.24).
  • Revenue of $14.2 million, missed the consensus of $14.72 million, increased 46% Y/Y primarily due to increased U.S. treatment session revenue.
  • Treatment session revenue reached $10.8 million, +65% Y/Y comparable to second quarter 2019 revenue, primarily driven by increased per click treatment session volume.
  • U.S. treatment session revenue per active site was $12,001 compared to $7,406 during the second quarter of 2020.
  • Revenues from NeuroStar Therapy System increased 10% Y/Y to $2.6 million because of the higher average selling price and sold 37 systems in the quarter (35 in Q2 2020).
  • The gross margin improved to 80.6%, increasing approximately 440 basis points from Q2 of 2020. Cash and cash equivalents totaled $115.8 million.
  • Outlook: Neuronetics reaffirmed an FY21 revenue outlook of $59 million - $63 million. For Q3, it forecasts sales of $15 million - $16 million, lower than the $16.51 million consensus.
  • Price Action: STIM shares are down 42.8% at $7.45 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!